References
1. Miyaki M, Iijima T, Ohue M, et al. A novel case with germline p53 gene mutation having concurrent multiple primary colon tumours. Gut 2003;52(2):304-306. doi:10.1136/gut.52.2.304.
2. Cho Y, Kim J, Kim Y, Jeong J, Lee KA. A case of late-onset Li–Fraumeni-like syndrome with unilateral breast cancer. Ann Lab Med 2013;33(3):212-216. doi:10.3343/alm.2013.33.3.212.
3. Choi MC, Bae JS, Jung SG, et al. Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or Fallopian tube. J Gynecol Oncol 2018 Jul;29(4):e43. doi:10.3802/jgo.2018.29.e43. Epub 2018 Mar 26.PMID:29770616.
4. Momozawa Y, Iwasaki Y, Parsons MT, et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun 2018 Oct 4;9(1):4083. doi:10.1038/s41467-018-06581-8.
5. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012 Mar 1;119(9):2114-2121. doi:10.1182/blood-2011-08-375758. Epub 2011 Dec 20.
6. Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 2011 Nov 14;4:46. doi:10.1186/1756-8722-4-46.
7. Nechiporuk T, Kurtz SE, Nikolova O, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov 2019 ;9(7):910-925. doi:10.1158/2159-8290.CD-19-0125. Epub 2019 May 2.
8. Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood 2017;130(6):699-712. doi:10.1182/blood-2017-02-763086. Epub 2017 Jun 12.
9. Gargallo P, Yáñez Y, Segura V, et al. Li–Fraumeni syndrome heterogeneity. Clin Transl Oncol 2020;22(7):978-988. doi:10.1007/s12094-019-02236-2. Epub 2019 Nov 5.